← Back to search

Agios Pharmaceuticals Inc

AGIO · NASDAQ

Pharmaceutical Preparation Manufacturing

Agios is focused on discovering and developing novel investigational medicines to treat malignant hematology, solid tumors and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across these three therapeutic areas, Agios has two approved oncology precision medicines and multiple first-in-class investigational therapies in clinical and/or preclinical development.

ESG Scores

Overall ESG
3.6
Environmental
3.2
Social
3.2
Governance
6.1

Public ESG Grades

Overall: BBB (High)
E: AS: BBG: BB

Gender Diversity

Female Directors0.4%
Female Executives0.3002070393374741%
Women in Workforce0.569%
CEO GenderMale

Market Data

Price$27.07-8.07 (-22.97%)
Market Cap$1.54B
P/E Ratio
EPS$—
52W High$46.00
52W Low$22.24
Beta0.77